Bioretec

32 articles about Bioretec

• Notice of Annual General Meeting (AGM) of Bioretec Ltd

  4/5/2024

  The shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 26 April 2024 at 10:00 a.m.

• Inside information: Bioretec's RemeOs™ biodegradable magnesium alloy composition has been allowed a patent by the U.S. Patent office

  3/21/2024

  Bioretec Ltd., a pioneer in biodegradable orthopedic implants, has been allowed a patent by the U.S. patent office for its RemeOs™ magnesium alloy composition.

• Bioretec Ltd's Annual Report and Financial Statements 2023 published

  3/15/2024

  Bioretec Ltd has published its 2023 Annual Report, Financial Statements and Report by the Board of Directors.

• Bioretec Ltd's financial statements bulletin 2023: Another successful year in the growth trajectory

  2/16/2024

  This announcement is a summary of Bioretec Ltd's financial statements bulletin for January-December 2023.

• Bioretec Ltd's schedule for financial reporting in 2024 and updates in the disclosure policy

  12/11/2023

  In the future, in addition to the financial statements bulletin and half-year report, Bioretec will also publish business reviews for January–March and January–September.

• Inside information: Bioretec's Board of Directors to initiate a new CEO recruitment process

  11/16/2023

  Bioretec Ltd, a pioneer of biodegradable orthopedic implants, is initiating a new CEO recruitment process as the company's current CEO, Mr. Timo Lehtonen, shall transfer into a new role within the company.

• Bioretec Ltd's Board of Directors has decided on a new option program 2023-1

  10/20/2023

  The Board of Directors of Bioretec Ltd has on 20 October 2023 decided, on the basis of the authorization received from the company's Annual General Meeting on 26 May 2023, to establish a new option program as an incentive scheme for the employees and consultants and members of the company's Key Opinion Leader group of the company and its subsidiaries.

• Inside information: Bioretec enters into the U.S. distribution agreement with Spartan Medical for the RemeOs™ screws

  9/12/2023

  Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, has signed a distribution agreement for the U.S. market with Spartan Medical Inc.

• Bioretec has received Business Finland's R&D grant for developing coatings for the next generation of biodegradable implants

  9/6/2023

  Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, has received a grant of a maximum of EUR 0.97 million for its research and development work from Business Finland's Co-Innovation project funding for the period 1 March 2023 - 28 February 2025.

• Bioretec unveils its revitalized Scientific Advisory Board (SAB), focusing on driving innovations in orthopedic implants

  8/16/2023

  Bioretec Ltd, a pioneering company dedicated to advancing orthopedic biodegradable implants, has refined and expanded its esteemed Scientific Advisory Board.

• Bioretec Ltd invests in a CNC machining center to increase the RemeOs™ production capacity

  6/13/2023

  Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland.

• Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

  5/26/2023

  The Annual General Meeting of Bioretec Ltd was held on 26 May 2023 in Tampere, Finland.

• Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team

  5/16/2023

  Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company's U.S. commercialization strategy from a clinical and regulatory perspective.

• FDA approves Bioretec's RemeOs™ trauma screw as the first bioresorbable metal implant in the U.S. market

  3/30/2023

  Bioretec Ltd. has received market authorization for its RemeOs™ trauma screw in the U.S. The RemeOs™ trauma screw is the first and currently only bioresorbable metal implant approved by the U.S. Food and Drug Administration.

• Bioretec is the first in the world to receive FDA approval for a bioresorbable metal product

  3/30/2023

  Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has announced receiving the market authorization of the U.S. Food and Drug Administration for its pioneering RemeOs™ trauma screw to be used for healing of bone fractures aligned with the clinical trial.

• Bioretec Ltd's Annual Report and Financial Statements 2022 are published

  3/17/2023

  Bioretec Ltd has published its 2022 Annual Report, Report by the Board of Directors, and Financial Statements.

• Bioretec postpones Annual General Meeting to a later date

  3/17/2023

  Bioretec Ltd's Board of Directors has decided to reschedule the date of the company's Annual General Meeting planned for April 14, 2023.

• Bioretec Ltd's financial statements bulletin 2022: We are delighted about the sales growth and look forward to future approvals

  2/17/2023

  This is a summary of Bioretec Ltd's financial statements bulletin for January-December 2022.

• Bioretec has submitted additional information requested by the FDA for US registration of RemeOs™ Trauma Screws, and the estimated approval timeline of April 2023 remains unchanged

  1/4/2023

  Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has finalized the supplement for market authorization request in accordance with the De Novo registration process concerning the company's RemeOs™ trauma screw, and FDA has now confirmed having received the supplement.

• Bioretec updates its estimate of the timing for approval of the CE mark for the RemeOs™ trauma screw

  11/4/2022

  Bioretec Ltd, a pioneer in biodegradable orthopedic implants, expects the European marketing authorization for the RemeOs™ trauma screw to be delayed from the original estimate of 2022.